1. Home
  2. ANNX vs VYX Comparison

ANNX vs VYX Comparison

Compare ANNX & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$3.75

Market Cap

726.1M

Sector

Health Care

ML Signal

HOLD

Logo NCR Voyix Corporation

VYX

NCR Voyix Corporation

HOLD

Current Price

$8.38

Market Cap

994.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANNX
VYX
Founded
2011
1881
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
726.1M
994.1M
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
ANNX
VYX
Price
$3.75
$8.38
Analyst Decision
Buy
Buy
Analyst Count
10
6
Target Price
★ $15.43
$12.67
AVG Volume (30 Days)
★ 3.4M
2.5M
Earning Date
11-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $7,156,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 15.29
52 Week Low
$2.54
$6.02
52 Week High
$7.18
$12.02

Technical Indicators

Market Signals
Indicator
ANNX
VYX
Relative Strength Index (RSI) 42.75 62.82
Support Level $3.71 $6.64
Resistance Level $4.37 $8.46
Average True Range (ATR) 0.24 0.37
MACD 0.02 0.21
Stochastic Oscillator 43.65 87.15

Price Performance

Historical Comparison
ANNX
VYX

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About VYX NCR Voyix Corporation

NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in two reportable segments: Retail, and Restaurants. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The company derives maximum revenue from Retail segment. Geographically, the company operates in United States, Americas (excluding United States), Europe, Middle East and Africa, and Asia Pacific. It derives maximum revenue from United States.

Share on Social Networks: